• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Citalopram decreases agitation in the context of Alzheimer's disease, but at doses higher than those commonly prescribed and at the expense of side effects
Commentary on: Porsteinsson AP, Drye LT, Pollock BG, et al.. Effect of citalopram on agitation in Alzheimer disease. The CitAD randomised clinical trial. JAMA 2014;311:682–91. Context By 2050, an estimated 135 million people will suffer from dementia globally.1 Caring for those with Alzheimer's disease (AD)—by far the most common form of dementia—is expensive, costing an estimated £23 billion per annum in the UK. As the disease progresses, neuropsychiatric symptoms such as depression, agitation and behavioural disturbance appear. The incidence of these symptoms, which predict institutionalisation an...
Source: Evidence-Based Medicine - September 15, 2014 Category: Internal Medicine Authors: Underwood, B. R., Fox, C. Tags: Neurogastroenterology, Geriatric medicine, Dementia, Drugs: CNS (not psychiatric), Sleep disorders (neurology), Stroke, Drugs: psychiatry, Eating disorders, Memory disorders (psychiatry), Psychiatry of old age, Psychotic disorders (incl schizophrenia), Sl Source Type: research